Fwd: Clinical experiences with extracorporeal Ultrasound-guided high-intensity focused ultrasound treatment for cancer patients.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 7, 2008 at 2:25 AM
Subject: Clinical experiences with extracorporeal Ultrasound-guided high-intensity focused ultrasound treatment for cancer patients.
To: mesothelioma77@gmail.com


[1]J Acoust Soc Am. 2008 May; 123(5): 2995
Wu F

Noninvasive, image-guided tumour thermal ablation with extracorporeal high-intensity focused ultrasound (HIFU) has received increasing interest in the treatment of patients with solid tumours. Since December 1997, an extracorporeal ultrasound-guided HIFU system (Mode-JC, Haifu Technology Co. Ltd., Chongqing, China) has been used to treat approximately 10,000 patients with solid tumours in China, including those of liver, breast, bone, kidney, pancreas, soft tissue, and uterus. The same device has been recently introduced into the UK, Italy, Japan, and South Korea, and so far, more than 1,000 patients have received HIFU treatment outside China. The purpose of this article is to introduce our clinical experiences using extracorporeal, ultrasound-guided HIFU ablation for solid tumours. Five-year follow-up data are observed in patients with primary liver cancer, breast cancer, and osteosarcoma. Among patients treated with HIFU, an extremely low major complication rate is observed. In conclusion, our clinical studies indicate that HIFU treatment is a safe, effective, and feasible modality in the treatment of cancer patients.



___
Source: http://www.hubmed.org/display.cgi?uids=18529307
--
 , Inc

 

Fwd: The Individualization of Cancer Therapy: The Unexpected Role of p53.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 7, 2008 at 2:25 AM
Subject: The Individualization of Cancer Therapy: The Unexpected Role of p53.
To: mesothelioma77@gmail.com


[1]Trans Am Clin Climatol Assoc. 2006; 117: 85-101
Hait WN, Yang JM

Our laboratory discovered that p53 can regulate the sensitivity to cancer therapies by affecting three critical aspects of cancer pharmacology: 1). The expression of drug targets; 2). the access of drugs to intracellular targets; and the response to DNA damage. We review the effects of p53 on antimicrotubule drugs through transcriptional regulation of MAP4 and stathmin (Oncoprotein 18). These two p53-regulated proteins control microtubule dynamics, regulate the sensitivity to taxanes and vinca alkaloids by changing the polymerization dynamics of tubulin and affecting the binding of drugs to microtubules. We found that overexpression of MAP4 increased microtubule polymerization and increased taxane binding and sensitivity. Overexpression of stathmin, a microtubule destabilizer, virtually abolished cellular taxane binding and increased resistance by over 1000-fold. Yet, despite an increased binding of vinca alkaloids to stathmin transfectants, we did not observe increased drug sensitivity. This was explained, at least in part, by a delay in G2/M transit. We also discovered that p53 could regulate the expression of multidrug resistance protein-1 (MRP1), a member of the ABC family of transporters that mediates the sensitivity to vinca alkaloids and anthracyclines. We found that as prostate cancer progressed from low stage/low grade to high stage/high grade there was an increased expression of both MRP1 and staining for p53, a surrogate for p53 mutations. We went on to show that p53 regulated the expression of MRP1 and that this produced resistance to doxorubicin and vinblastine. We further demonstrated that MRP1 overexpression blocked the accumulation of flutamide and hydroxy-flutamide (the active metabolite) without affecting transport of dihydrotesterone, thereby blocking access of the anti-androgen but not the androgen to intracellular androgen receptors. Finally, we reviewed the effects of DNA damage on p53 expression and MAP4 repression as a means to increase the effectiveness of breast cancer treatment. These data demonstrated the possibility of individualizing treatment based on p53 status.



___
Source: http://www.hubmed.org/display.cgi?uids=18528466
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: High-resolution melting analysis for rapid screening of BRCA1 and BRCA2 Spanish mutations.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 7, 2008 at 2:25 AM
Subject: High-resolution melting analysis for rapid screening of BRCA1 and BRCA2 Spanish mutations.
To: mesothelioma77@gmail.com


[1]Breast Cancer Res Treat. 2008 Jun 5;
de Juan I, Esteban E, Palanca S, Barragán E, Bolufer P

The majority of BRCA1 and BRCA2 mutation detection procedures include screening methods, all of which are time-consuming. High-resolution melting (HRM) is a promising pre-screening method of gene scanning that combines simplicity and rapid identification of genetic variants. We evaluated HRM in the screening of BRCA1/2 Spanish mutations. We studied 40 BRCA1 and 47 BRCA2 DNA samples with different Spanish mutations. We included a group of 20 unknown DNAs from patients with sporadic breast cancer (BC). The assay was performed with the LightCycler((R)) 480 Instrument (Roche). The HRM discriminates all the BRCA1/2 Spanish mutations studied from wild-type DNA. Besides, 54 out of 87 mutations were clearly differentiated from each other. In sporadic BC 11 polymorphisms and three unclassified variants were found in both genes. HRM is a valuable method for rapid screening of BRCA1/2 Spanish mutations and is capable of differentiating new genetic variants in PCR products.



___
Source: http://www.hubmed.org/display.cgi?uids=18528753
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc